Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.65 |
| ▸ | STAT3 | P40763 | 2/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL1B | P01584 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403109 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL19451294 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL29403026 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL21814694 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL24142128 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL19451416 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL23884378 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL17873760 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL23884163 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL29856029 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-11547759-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021201577-A1 | HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2021-10-07 | — | — | WO | disclosed |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2021-09-23 | — | — | US | disclosed |
| US-20200282068-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | CRBN 256/4885DDB1 2125/4885HDAC1 508/4885 |
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 235/4885DDB1 2244/4885HDAC1 468/4885 |
| US-20200282068-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 235/4885DDB1 2244/4885HDAC1 468/4885 |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 235/4885DDB1 2244/4885HDAC1 468/4885 |
| US-11547759-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | CRBN 256/4885DDB1 2125/4885HDAC1 508/4885 |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 235/4885DDB1 2244/4885HDAC1 468/4885 |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885HDAC1 920/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885HDAC1 920/4885 |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 256/4885DDB1 2125/4885HDAC1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.